Feed TRAW
TR

Traws Pharma, Inc. TRAW · NASDAQ

$0.22 +0.82% (+$0.00)

Summary

63 / 100 · Bulios Score

What speaks for it

  • Out of every 100 USD of revenue, 329 USD is left as net profit.
  • Revenue grew by 131% a year over the last 3 years.
  • It earns 3,379 USD a year on every 100 USD of invested capital.
  • It has no debt and holds $3.13M in cash.

What to watch

  • It passes only 1 of the 9 points of the Piotroski financial health test.
  • It reports a profit, yet spends more cash than it brings in.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap
Bulios Fair Price
Current price $0.22
P/E today 0.4
Biotechnology industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 0.4 USD for 1 USD of yearly profit.

Valuation in detail

Is it growing?

Yes, fast

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

Revenue grew by 65% a year over 5 years. Over the last 3 years it grew by 131% a year.

Growth in detail

Does it make money?

Income figures for the last 12 months are not available.

Profitability in detail

Is it financially healthy?

Yes

It has no debt. The debt score is low because of the debt-to-equity ratio.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Neutral

Today's price within the analysts' price targets

The average target of $1 is 351% above today's price. 0.0% of the analysts recommend buying.

Analysts in detail

What does it earn on?

By product

The company reports no revenue by product.

By region

The company reports no revenue by region.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy